However, Li et al. reported that the antitumor ability of TP53 mutant samples was significantly lower than that of TP53 wild type in STAD and COAD.39 This difference may be due to the breaking of the balance between the TMB and the tumor aneuploidy level (TAL) on tumor immunity caused by a gene mutation. Here, TP53 is linked to neoplasm.